Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP21 with or without epirubicin for TACE in hepatocellular carcinoma
CTR20181994Phase 2Active
- Sponsor
- Beijing Suopingda Medical Research
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dicycloplatin in hepatocellular carcinoma (HCC), sponsored by Beijing Suopingda Medical Research. Started Mar 2019; status: active.
02
Drugs
dicycloplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20181994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181994.